TWD 79.5
(-3.52%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 626.46 Million TWD | 21.89% |
2022 | 513.96 Million TWD | 9.78% |
2021 | 468.18 Million TWD | 5.11% |
2020 | 445.44 Million TWD | -1.86% |
2019 | 453.87 Million TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 688.95 Million TWD | 9.97% |
2024 Q2 | 762.11 Million TWD | 10.62% |
2023 Q4 | 626.46 Million TWD | 10.81% |
2023 FY | 626.46 Million TWD | 21.89% |
2023 Q3 | 565.34 Million TWD | -3.6% |
2023 Q2 | 586.47 Million TWD | 11.23% |
2023 Q1 | 527.24 Million TWD | 2.58% |
2022 FY | 513.96 Million TWD | 9.78% |
2022 Q4 | 513.96 Million TWD | 0.0% |
2021 FY | 468.18 Million TWD | 5.11% |
2020 FY | 445.44 Million TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
DIVA Laboratories, Ltd. | 210.93 Million TWD | -197.0% |
Genetics Generation Advancement Corp. | 164.9 Million TWD | -279.89% |
Welgene Biotech Co.,Ltd. | 247.89 Million TWD | -152.715% |
Puriblood Medical Co., Ltd. | 84.35 Million TWD | -642.689% |
TFBS Bioscience Inc. | 187.43 Million TWD | -234.229% |